Biotechnology

United Therapeutics

$167.71
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.57 (+0.34%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell UTHR and other stocks, options, and ETFs commission-free!

About UTHR

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD. The listed name for UTHR is United Therapeutics Corporation Common Stock.

CEO
Martine A. Rothblatt
Employees
920
Headquarters
Silver Spring, Maryland
Founded
1996
Market Cap
7.63B
Price-Earnings Ratio
15.81
Dividend Yield
—
Average Volume
374.35K
High Today
$168.89
Low Today
$164.62
Open Price
$166.73
Volume
203.48K
52 Week High
$176.31
52 Week Low
$75.58

Collections

UTHR Earnings

$0.00
$1.29
$2.59
$3.88
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 24, Pre-Market

You May Also Like

NDLS
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure